Talking the Cure by Hogan Lovells

Talking The Cure: Exploring the industry with Philip Katz - Part 2

In the second part of our two-part interview with Philip Katz, head of the Hogan Lovells Pharmaceuticals and Biotechnology Regulatory Practice, we discuss team management, diversity and we also get to learn about Phil, when he shuts down his blackberry. We had a lot to cover in our conversation with Phil, so if you haven't checked out yet, listen to the first part of our conversation.

Talking The Cure: Exploring the industry with Philip Katz - Part 1

In the first episode of our two-part interview with Philip Katz, head of the Hogan Lovells Pharmaceuticals and Biotechnology Regulatory Practice, we discuss developments in the pharmaceuticals and biotechnology industry, the global practice of law in this space, and we also get to learn about Phil and his career journey. We had a lot to cover in our conversation with Phil, so stay tuned for more industry insights in part two of our interview!

Talking the Cure: Discussing venture capital in the life sciences and health care sector in Germany

In this episode, our partners Jörg Schickert and Nikolas Zirngibl talk with Jörn Bungartz, an adviser in the digital health sector, about opportunities and barriers for venture capital in the life sciences and health care industry in Germany.
You can find additional thought leadership and information regarding venture capital in the life sciences and health care industry on HL Engage.
If you are interested in more information all around Life Sciences and Health Care, follow us on LinkedIn and Twitter.

Talking The Cure: Discussing European developments on Covid-19

In this episode, Elisabethann Wright, Jane Summerfield, and Hein Van den Bos talk about developments in Belgium, the UK, and the Netherlands and how the Covid-19 pandemic impacts clinical trials and the authorization process of the local authorities.

Talking The Cure: Discussing reimbursement issues in France and the MDR

In this episode, Charlotte Damiano and Fabien Roy talk about reimbursement issues, early access and the collection of clinical data in France. In the end they both address general developments of the medical device regulation.
You can find additional thought leadership and information regarding Medical Devices and Technology Regulatory on HL Engage.
If you are interested in more information all around Life Sciences and Health Care, follow us on LinkedIn and Twitter.

Talking the Cure: Discussing COVID-19’s impact on FDA’s inspection program and next steps after the pandemic

In this episode, Phil Katz and Jim Johnson continue their conversation about the impact of COVID-19 on FDA’s drug inspection program and the steps companies should take now and in preparation for when the pandemic is coming to an end.
For all updates around COVID-19, visit our COVID-19 hub.
You can find additional thought leadership and information regarding Medical Devices and Technology Regulatory on HL Engage.
If you are interested in more information all around Life Sciences and Health Care, follow us on LinkedIn and Twitter.

Talking The Cure: Discussing how the coronavirus pandemic is affecting the pharmaceutical industry and FDA

In this episode, Phil Katz, David Horowitz, and Jim Johnson explore the impact on industry and FDA of the agency’s decision to halt foreign inspections and take other steps that reduce international activities. They anticipate further steps by the agency and talk about how companies can strategically address the implications, which create obstacles but also opportunities.

Talking The Cure: Discussing FDA authorities for handling a global pandemic for medical devices

In this episode, Michael S. Heyl and Jonathan S. Kahan explore questions around FDA’s Emergency Use Authorization authorities, how it has been used historically, and how it may be used for the coronavirus. They highlight very recent FDA actions and project how these authorities could be applied to address supply chain issues, in addition to the development of new technologies/devices to aid in the diagnosis and treatment of the virus.